1.015
0.98%
-0.005
전일 마감가:
$1.02
열려 있는:
$1.01
하루 거래량:
52,366
Relative Volume:
0.36
시가총액:
$6.47M
수익:
-
순이익/손실:
$-6.07M
주가수익비율:
-0.1346
EPS:
-7.54
순현금흐름:
$-7.34M
1주 성능:
-11.40%
1개월 성능:
-5.61%
6개월 성능:
-27.86%
1년 성능:
-53.67%
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
명칭
Adial Pharmaceuticals Inc
전화
434-422-9800
주소
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
ADIL을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
ADIL | 1.01 | 6.47M | 0 | -6.07M | -7.34M | -7.54 |
VRTX | 449.44 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 746.00 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 596.25 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 247.31 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 107.90 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2018-10-30 | 개시 | Maxim Group | Buy |
2018-10-11 | 개시 | Dawson James | Buy |
Adial Pharmaceuticals Inc 주식(ADIL)의 최신 뉴스
Adial Pharmaceuticals (NASDAQ:ADIL) Coverage Initiated at Rodman & Renshaw - Defense World
RODMAN&RENSHAW Upgrades Adial Pharmaceuticals (NASDAQ:ADIL) to “Strong-Buy” - Defense World
Rodman & Renshaw sets stock target, buy rating on Adial Pharma, cites potential - Investing.com India
ARMISTICE CAPITAL, LLC Acquires New Stake in Adial Pharmaceutica - GuruFocus.com
U.S. STOCKS Oklo, Adial Pharma, Sonos - XM
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder - AOL
Adial Pharmaceuticals completes key study for FDA meeting - Investing.com
Adial Pharmaceuticals Announces Positive Topline Results - GlobeNewswire
Adial Pharma's AD04 Drug Hits Key Milestones in Alcohol Use Disorder Treatment Study | ADIL Stock News - StockTitan
This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Adial Pharma Reports Mixed Q3: AUD Drug Study Advances Despite Widening Losses | ADIL Stock News - StockTitan
Adial Pharmaceuticals Appoints Vinay Shah as CFO - Defense World
Adial Pharmaceuticals names new CFO amid strategic growth By Investing.com - Investing.com Australia
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - GlobeNewswire
Adial Pharmaceuticals names new CFO amid strategic growth - Investing.com
Adial Pharma Taps Veteran CFO with $150M+ Fundraising Track Record | Key Executive Move | ADIL Stock News - StockTitan
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference - The Manila Times
EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate - AOL
Adial Pharmaceuticals patent expands for alcohol disorder drug - Investing.com
Adial Pharmaceuticals patent expands for alcohol disorder drug By Investing.com - Investing.com Canada
Adial Pharmaceuticals Receives Notice of Allowance for U.S. - GlobeNewswire
Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery - GlobeNewswire
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 46.2% in September - Defense World
Analyzing ADI’s price-to-book ratio for the last quarter - US Post News
Adial Pharmaceuticals completes key study stage for AUD drug - Investing.com
Adial Pharmaceuticals Announces Database Lock in - GlobeNewswire
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - StockTitan
Analog Devices Inc. (ADI) Stock: A Year of Declines and Increases - The InvestChronicle
MQS Management LLC Increases Stock Position in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Addex Therapeutics Reports Profitable H1 2024 - TipRanks
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit - GlobeNewswire
Recent Insider Activity Could Benefit Adaptimmune Therapeutics Plc ADR (ADAP) - Knox Daily
ADMA Biologics stock soars to all-time high of $19.36 - Investing.com
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest? - Yahoo Finance
Adial Pharmaceuticals (NASDAQ:ADIL) versus Galapagos (NASDAQ:GLPG) Head-To-Head Comparison - Defense World
Analog Devices (NASDAQ:ADI) shareholders notch a 17% CAGR over 5 years, yet earnings have been shrinking - Yahoo Finance
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement - Eagle-Tribune
ADM Investor Services Singapore Becomes Abaxx Exchange's Third Clearing and Trading Member - GlobeNewswire
Raymond James lifts Adma Biologics Inc [ADMA] price estimate. Who else is bullish? - The DBT News
Keeping an Eye on Adma Biologics Inc (ADMA) After Insider Trading Activity - Knox Daily
Adma Biologics Inc (NASDAQ:ADMA) stock crossing the finish line today - US Post News
Analytical Overview: Adma Biologics Inc (ADMA)’s Ratios Tell a Financial Story - The Dwinnex
A new trading data show Adaptimmune Therapeutics Plc ADR (ADAP) is showing positive returns. - SETE News
ADIA Nutrition Stakes Claim in $6.7B Industry with Strategic Trademark Expansion - Marketscreener.com
ADMA Biologics set to join S&P SmallCap 600 index By Investing.com - Investing.com Canada
Take off with Applied Dna Sciences Inc (APDN): Get ready for trading - SETE News
ADMA Biologics Set to Join S&P SmallCap 600 Index - Yahoo Finance
Adma Biologics Inc (ADMA) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Adma Biologics Inc (ADMA) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Adial Pharmaceuticals Inc (ADIL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):